Skip to main content

Table 2 Summary of c-DMARDs and b-DMARDs prescribed in the cohort

From: Real-world data reveals the complexity of disease modifying anti-rheumatic drug treatment patterns in juvenile idiopathic arthritis: an observational study

  Persistent oligoarticular JIA (n = 78) Extended oligoarticular JIA (n = 56) Polyarticular JIA RF- (n = 103) Polyarticular JIA RF + (n = 26) ERA (n = 62) Total (n = 325)
c-DMARD
Number of distinct c-DMARD prescribed (n, %)
  0 40 (51%) 6 (11%) 0 (0%) 0 (0%) 7 (11%) 53 (16%)
  1 32 (41%) 37 (66%) 65 (63%) 16 (62%) 38 (62%) 188 (58%)
   ≥ 2 6 (8%) 13 (23%) 37 (37%) 10 (38%) 17 (27%) 84 (26%)
c-DMARD types (n, %)
  Methotrexate 34 (44%) 45 (80%) 99 (96%) 26 (100%) 39 (63%) 243 (75%)
  Sulfasalazine  < 5 (< 6%) 7 (12%) 21 (20%)  < 5 (< 19%) 30 (48%) 66 (20%)
  HCQ 5 (6%) 6 (11%) 16 (16%) 6 (23%)  < 5 (< 8%) 36 (11%)
  Leflunomide  < 5 (< 6%) 6 (11%) 13 (13%)  < 5 (< 19%)  < 5 (< 8%) 26 (8%)
c-DMARD therapy combination
  Double c-DMARD 5 (6.4%) 8 (14%) 27 (26%) 9 (35%) 12 (19%) 61 (19%)
  Triple c-DMARD 0  < 5 (< 9%)  < 5 (< 5%)  < 5 (< 19%) 0 5 (2%)
b-DMARD
Number of distinct b-DMARD prescribed (n, %)
  0 69 (88%) 31 (55%) 40 (39%) 8 (31%) 30 (48%) 178 (55%)
  1 9 (12%) 22 (39%) 46 (45%) 13 (50%) 21 (34%) 111 (34%)
   ≥ 2 0  < 5 (< 9%) 17 (16%) 5 (19%) 11 (18%) 36 (11%)
b-DMARD types (n, %)
  Etanercept  < 5 (< 6%) 14 (25%) 44 (43%) 15 (58%) 25 (40%) 102 (31%)
  Adalimumab  < 5 (< 6%) 9 (16%) 21 (20%)  < 5 (< 19%) 13 (21%) 51 (16%)
  Tocilizumab  < 5 (< 6%)  < 5 (< 9%) 11 (11%)  < 5 (< 19%)  < 5 (< 8%) 17 (5%)
  Othersa 0  < 5 (< 9%) 13 (13%)  < 5 (< 19%) 10 (16%) 28 (9%)
  1. JIA Juvenile idiopathic arthritis, RF Rheumatoid factor negative, RF Rheumatoid factor positive, ERA Enthesis-related arthritis, c-DMARD Conventional disease anti-rheumatic drugs, b-DMARD Biologic disease anti-rheumatic drugs, HCQ Hydroxychloroquine
  2. aGolimumab, infliximab, tofacitinib, abatacept, and secukinumab